Posted by Michael Wonder on 26 Jul 2022
MHRA grants marketing authorisation for GBT’s Oxbryta (voxelotor) for use in Great Britain for the treatment of haemolytic anaemia in patients with sickle cell disease age 12 years and older
26 July 2022 - Voxelotor is the first medicine approved in Great Britain to directly inhibit sickle haemoglobin polymerisation, the underlying molecular cause of sickle cell disease.
Global Blood Therapeutics today announced that the MHRA has granted Great Britain marketing authorisation for Oxbryta (voxelotor) for the treatment of haemolytic anaemia due to sickle cell disease in adult and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxyurea.
